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the	stability	criteria	 for	all	 the	preanalytical	conditions.	The	SCT	tests	 (normalized	
screen,	confirm,	and	screen/confirm	ratio)	met	the	stability	criteria	only	when	treated	
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1  | INTRODUC TION
The	results	of	lupus	anticoagulant	(LA),	together	with	anticardiolipin	
and	 anti–beta2‐glycoprotein	 I	 antibodies,	 will	 guide	 the	 anticoag‐







alter	 LA	 results	 significantly.7‐9	 The	 latest	 guideline	 recommends	
freezing	 the	plasma	 if	LA	cannot	be	analyzed	within	4	hours	after	











Labor‐intensive	 and	 cumbersome	 procedures	 are	 prone	 to	 er‐
rors,	 and	 if	 possible,	 the	 preanalytical	 recommendations	 for	 LA	




optimal	 preanalytical	 conditions	may	 occur.	 The	 aim	 of	 this	 study	
was	to	investigate	how	different	preanalytical	conditions	change	the	
LA	results	and	their	interpretation.
2  | MATERIAL S AND METHODS
2.1 | Subjects
The	 study	was	 approved	by	 the	Regional	 Ethical	Committee	 (REC	
number	 2010/2037‐4).	 Patients	 >18	 years,	 living	 in	 the	 proximity	
of	 the	hospital	 laboratory,	who	had	positive	or	negative	 results	of	








Blood	 sampling	 was	 performed	 at	 the	 Department	 of	 Medical	
Biochemistry	 and	 Pharmacology	 (Haukeland	 University	 Hospital)	
on	 three	 separate	 days	 from	 February	 through	 May	 2014.	 The	




guideline5	with	double	centrifugation	 (2000	g	 in	15	minutes,	 then	
2600 g	in	10	minutes)	to	achieve	platelet‐poor	plasma	(<10	×	109/L)	
and	 analyzed	 within	 4	 hours	 (stored	 in	 room	 temperature)	 after	
the	blood	draw	(Figure	1,	condition	A1).	In	condition	A2,	aliquoted	
plasma	from	A1	was	stored	for	24	hours	before	analyzed	(to	mimic	
double‐centrifuged	 aliquoted	 “fresh”	 plasma	 being	 received	 from	
another	 hospital).	 In	 condition	 B,	 citrated	 blood	 was	 centrifuged	
at	1500	g	 (single	 centrifugation)	within	4	hours,	 then	double‐cen‐
trifuged	 after	 24	 hours	 and	 then	 analyzed	 (to	mimic	 fresh	 single‐
centrifuged	 aliquoted	 plasma	 received	 from	 smaller	 centers	 not	






transportation	 legs).	 The	 samples	 were	 not	 agitated	 in‐between	
transport.	In	the	remaining	storage	time,	the	samples	were	stored	at	
room	temperature	(18‐22°C).	Double‐centrifuged	aliquoted	plasma	
from	 conditions	A1,	A2,	B,	 and	C	was	 frozen	 at	minus	80°C	 in	 1‐
mL	microtubes	with	screw	cap	(A1−80°C,	A2−80°C,	B−80°C,	and	C−80°C),	
mimicking	 the	situation	when	the	 laboratory	does	not	analyze	 the	






2.3 | Reagents, instruments, and reporting of results
All	 samples	 were	 analyzed	 by	 the	 DRVVT	 screen	 and	 confirm	
(STAGO)	and	the	APTT	test	SCT	screen	and	confirm	(Instrumentation	
Laboratories)	 on	 the	 STA‐R	 Evolution	 instrument	 (STAGO).	 The	




clotting	 time	 for	 the	 screen	 test	 is	 accompanied	by	 a	 significantly	
shortened	clotting	time	for	the	confirm	test,	is	indicative	of	a	posi‐
tive	LA	result.	This	will	be	evident	by	a	normalized	screen/confirm	
ratio	higher	 than	 the	 cutoff	 (99th	percentile	derived	 from	healthy	
persons	as	recommended	by	the	ISTH	guideline5).	In	patients	treated	
with	warfarin,	 results	 should	be	 interpreted	with	 caution,	 as	 both	
screen	 and	 confirm	 tests	 may	 be	 prolonged,	 and	 the	 normalized	
screen/confirm	 ratio	may	be	higher	 than	 in	nonanticoagulated	pa‐
tients	(“false‐positive”	results).	Mixing	tests	were	not	performed	in	
this	study.	The	DRVVT	and	SCT	reagents	used	in	the	present	study	
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contain	a	heparin	 inhibitor	 to	avoid	 interference	of	unfractionated	
heparin	 and	 low	molecular	weight	heparin	up	 to	 certain	 levels	 (ie,	
0.5‐0.8	IU/mL	and	1	IU/mL,	respectively).
As	 recommended,	 normal	 pooled	 plasma	 (NPP)	was	 analyzed	
in	 every	 run.	 A	 single	 batch	 of	NPP,	 prepared	 in‐house	 from	 40	
healthy	 donors	 according	 to	 the	 protocol	 A1−80°C,	 was	 used	
throughout	 the	study.	The	uncertainty	 in	 the	NPP	result	was	 re‐
duced	by	analyzing	 it	 four	 times	 in	every	 run.	Each	patient	 sam‐
ple	 result	 was	 divided	 by	 the	 mean	 NPP	 result	 (normalization).	
Results	were	given	as	normalized	DRVVTscreen	ratio	 (DRVVTSR)	 (ie,	
DRVVTscreen	 patient	 [seconds]/DRVVTscreen	 NPP	 [seconds])	 and	
normalized	DRVVTconfirm	 ratio	 (DRVVTCR)	 (ie,	DRVVTconfirm	patient	
(seconds)/DRVVTconfirm	 NPP	 (seconds).	 Normalized	 SCT	 results	
were	reported	similarly,	as	SCTSR	and	SCTCR.	The	outcome	of	the	
LA	 test	was	 finally	 determined	based	on	 the	normalized	 screen/
confirm	 ratio	 (DRVVTnormalized	 ratio	 [DRVVTNR])	 (ie,	 DRVVTSR/
DRVVTCR)	 and	 SCTNR	 (ie,	 SCTSR/SCTCR).	 In	 accordance	with	 the	
















2.4.1 | Criteria for sample stability according to 
allowable bias and total error (TE)
For	each	preanalytical	condition,	the	results	were	calculated	as	a	
percentage	of	 the	 corresponding	 results	 from	condition	A1.	The	
samples	were	 defined	 as	 stable	 if	 (a)	 the	 limits	 of	 the	90%	 con‐
fidence	 interval	 (CI)	 of	 the	mean	were	within	 100%	±	 allowable	
F I G U R E  1  The	different	preanalytical	(storage	and	centrifugation)	conditions	used	prior	to	the	lupus	anticoagulant	(LA)	analyses
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bias,	and	(b)	95%	of	the	individual	results	were	within	100%	±	al‐
lowable	 TE	 (ie,	 ~2	 individual	 results	 could	 be	 outside	 the	 limits	
for	 allowable	TE).	This	 is	 a	 general	 statistical	method,16,17 which 
is	 applicable	 also	 for	 clotting	 assays.	 Allowable	 bias	 was	 de‐










biological	 variation,	 and	 CVG	 is	 between‐subject	 biological	 vari‐
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derived	from	the	width	of	the	reference	interval,	as	shown	in	Table	
S2.	 The	 calculations	 based	 on	 the	 reference	 interval	 for	 SCTNR 
supported	 the	 use	 of	 the	widest	 limits	 (5%	 and	 13%)	 as	 quality	
specification	(Table	S2),	and	consequently,	these	were	chosen	for	
evaluation	of	both	tests.
2.4.2 | Reclassification of results based on 
sample stability
The	clinical	significance	of	alternative	preanalytical	conditions	for	
LA	 testing	was	 evaluated	based	upon	whether	 the	 classification	
of	the	results	from	condition	A1	changed	category	from	negative	
to	positive	or	vice	versa.	To	avoid	reclassification	based	purely	on	
analytical	 variation,	 results	 deviating	 less	 than	 ±1.96	 times	 the	





The	 initial	 analysis	 (guideline‐recommended	 preanalytical	 condition	
A1)	of	the	20	nonwarfarin	participants	resulted	in	12	negative	(both	
DRVVTNR	 and	SCTNR)	 and	 eight	 positive	 LA	 results	 (six	 positive	 for	
both	DRVVTNR	and	SCTNR	and	one	positive	 for	either	DRVVTNR or 






















3.3 | Reclassification of study participants based on 
sample stability
None	 of	 the	 participants	 in	 the	 study	were	 reclassified	when	 the	
guideline‐recommended	 condition	 (A1−80°C)	 was	 used,	 neither	 for	























































































































ative	 samples	 for	LA	were	 included.	Several	different	preanalytical	
conditions	 commonly	 faced	 by	 laboratories	were	 investigated,	 and	
the	 study	 also	 included	 an	 evaluation	of	 the	potential	 clinical	 con‐
sequences	 for	 the	study	participants.	According	 to	our	knowledge,	
such	 a	 comprehensive	 range	 of	 preanalytical	 conditions	 has	 not	
been	tested	before.	Another	strength	of	the	present	study	is	that	ac‐
ceptance	criteria	for	stability	were	defined	both	for	bias	and	for	TE.	
Several	 studies	 evaluating	 changes	 in	 hemostasis	 parameters	 only	
use	acceptance	criteria	 for	bias.	These	studies	state	 that	 the	mean	










A	 limitation	of	our	study	 is	 that	 the	number	of	 study	partici‐
pants	included	is	relatively	low.	This	is	compensated	for	by	includ‐
ing	 the	90%	CI	 for	 the	bias	 in	 the	quality	specification,	ensuring	
(ie,	with	90%	confidence)	that	the	bias	criterion	is	met.	However,	
it	 cannot	 be	 excluded	 that	more	 reclassifications	would	 occur	 if	
more	patients	were	included	or	if	the	samples	were	more	agitated	
by	longer	transportation.	In	addition,	the	99th	percentile	was	used	




of	 the	 biological	 variation	 data	 used	 to	 calculate	 the	 allowable	
limits	for	bias	and	TE.19	However,	the	suggested	limits	were	con‐
firmed	by	additional	calculations	of	biological	variability	based	on	







anticoagulants	 as	 anticoagulants	 usually	 cause	 prolonged	 clot‐
ting	 times,	which	may	 increase	 the	 risk	of	 erroneous	 interpreta‐
tion.28‐30	 It	 could	 be	 argued	 that	 samples	 from	warfarin‐treated	
patients	should	be	excluded,	especially	as	neither	mixing	test	re‐
sults	 nor	 cutoff	 especially	 for	 these	 patients	were	 evaluated.	 In	
addition,	 the	 group	 of	 warfarin‐treated	 patients	 are	 few;	 thus,	
it	 cannot	 be	 drawn	 firm	 conclusions	 regarding	 reclassifications.	








4.2 | Stability of LAs according to the chosen 
allowable bias and allowable TE
DRVVT	assays	were	stable	for	all	tested	preanalytical	conditions,	
while	SCT	assays	were	affected	by	several	of	the	conditions,	es‐
pecially	 conditions	 B	 and	 C.	 SCTSR	 and	 SCTCR	 were	 stable	 only	
for	 A1−80°C.	 This	 information	 should	 be	 notified	 by	 laboratories,	
which	 only	 perform	 confirmatory	 tests	 when	 screen	 results	 are	
prolonged.	The	reason	for	DRVVT	being	more	“robust”	than	SCT	
may	be	 that	 the	DRVVT	 tests	 are	 sensitive	only	 to	 the	 coagula‐
tion	factors	 in	 the	common	coagulation	pathway	 (fibrinogen,	FII,	
FV,	and	FX),	while	the	SCT	tests	are	also	sensitive	to	changes	 in	
the	 intrinsic	pathway	(factors	VIII,	 IX,	XI,	and	XII).	Consequently,	
the	 rapid	 decrease	 in	 both	 FV	and	 FVIII	 during	 storage	 in	 room	
temperature	of	citrated	blood20	and	aliquoted	plasma24	may	affect	
SCT	more	than	DRVVT.	The	reason	why	some	SCT	results	(SCTSR 
results	 from	C	and	C−80°C)	decreased	 is	 unclear,	 especially	 as	 the	
platelet	count	was	less	than	10	×	109/L	in	all	samples	before	freez‐
ing.	A	decrease	after	freezing,	in	spite	of	a	low	platelet	count,	was	




findings	 support	 the	 recommendations	 from	 the	 CLSI	 guideline	
advocating	follow‐up	LA	tests	when	a	strong	clinical	suspicion	of	
APS	remains	despite	a	negative	LA	result.4
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4.3 | Clinical consequences (reclassification) of 
different preanalytical conditions
In	contrast	to	the	studies	by	Froom11	and	Gosselin,12	where	several	
patients	 were	 reclassified,	 only	 one	 warfarin‐treated	 participant	
was	reclassified	from	positive	to	negative	for	three	of	the	different	





positive	 result	 to	 confirm	 the	 result	 to	 avoid	diagnosing	 antiphos‐
pholipid	syndrome	in	patients	where	this	is	not	persistent.	However,	
our	study	indicates	that	additional	follow‐up	samples,	preferentially	





The	 study	 demonstrates	 that	 the	 DRVVT	 assays	 (normalized	
screen,	confirm,	and	screen/confirm	ratios)	 in	nonanticoagulated	
patients	are	robust	regarding	suboptimal	preanalytical	conditions	
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